Introduction

ChondroFiller is increasingly recognised as an effective treatment for cartilage damage, offering a minimally invasive option to help preserve joint health and delay more extensive surgery. It works by supporting the natural repair of cartilage, which is crucial for maintaining smooth joint function. However, it is important to understand that ChondroFiller is not the right choice for every patient. Careful assessment of who is suitable helps ensure the best possible outcomes. In this article, we explore the types of patients for whom ChondroFiller may not be ideal, focusing on clinical conditions and specific health factors that require special attention.

Clinical Criteria: When ChondroFiller May Not Be Advisable

Before recommending ChondroFiller, clinicians conduct a detailed assessment involving scans and physical examinations. Patients who have very extensive cartilage damage, advanced arthritis, or large defects are often less likely to benefit from this treatment. Medical guidelines suggest that ChondroFiller works best for well-defined, moderate-sized cartilage injuries. This is because when damage is widespread or severe, the joint environment is less favourable for repair, and mechanical stability may be compromised.

Supporting this, one study described their patient groups according to disease stage: “Our study was aimed at the infiltration of ChondroFiller Liquid® on 43 patients, divided in two cohorts according to the Eaton-Littler classification (group A stage 1-2; group B stage 3-4).” This highlights how staging the severity of joint damage is key to deciding on treatment.

Further, practical factors affect who can receive ChondroFiller. “In many cases the accessibility is not easy, and the distance between the tip of the needle and the area to be treated is such that the efficiency of the release is difficult, if not impossible.” This means that certain joint locations or shapes might make treatment technically challenging or less effective.

A similar treatment, the autologous matrix-induced chondrogenesis (AMIC) technique, has strict inclusion criteria: “Inclusion criteria for implantation were FAI diagnosis (cam or pincer type), grade IV chondral lesions (Outerbridge size 2-4 cm2); Tönnis stage 0-II…” This underlines how important it is to carefully select patients based on lesion size and joint health.

Besides the damage itself, other health issues can rule out ChondroFiller. These include active infections near the joint, significant bone loss, instability, or misalignment that isn’t corrected. Conditions such as severe obesity, poor healing ability, or inflammatory joint diseases may also affect treatment success or safety. It’s clear that a full health review is critical to avoid complications and maximise benefits.

Age and Activity Level: Special Considerations

The question of whether older patients are suitable for ChondroFiller is a common concern. Older adults often have reduced healing capacity or more advanced arthritis, which can affect recovery and function after treatment. That said, age by itself shouldn’t automatically exclude someone. It’s how healthy the individual is overall, how advanced their joint condition is, and their personal goals that really matter.

One study reports impressive results: “The results of the study show that there was an improvement in pain symptoms, associated with an increase in force in the pincer and grip movements evaluated with clinical tests.” This confirms how important the right patient selection is for achieving pain relief and improved function.

Furthermore, research following patients for over two years found: “At 29 months following surgery… a significant improvement was obtained in all parameters assessed, focusing on the characteristics of the generated tissue in the MRI (MOCART scores).” This suggests that well-chosen patients can expect lasting and measurable benefits, including joint tissue regeneration.

Younger, more active people with smaller, well-defined cartilage defects typically make the best candidates for ChondroFiller. Their bodies often respond better to repair, and they generally have higher expectations for joint function. However, it’s crucial to set realistic goals that match the individual’s situation to ensure satisfaction and long-term success.

Alternatives and Special Patient Groups

If ChondroFiller isn’t suitable, other treatments are available depending on the situation. For example, bone cement plays an important role for patients with traumatic fractures, such as those of the femoral neck, or for bone loss due to cancer. This material provides immediate structural support and enjoys strong backing from professional organisations including the British Orthopaedic Association.

Different medical centres might favour varying approaches. Some use uncemented implants with excellent results for certain patients. This diversity reinforces the need to tailor treatments carefully based on the patient’s unique characteristics and the expertise of the care team.

Patient Experience and the Role of the Multidisciplinary Team

Assessing a patient’s suitability for ChondroFiller is best done in a professional, patient-focused setting. At MSK Doctors, expert clinicians led by Professor Paul Lee—a respected cartilage specialist and Regional Surgical Ambassador—offer expert guidance. With extensive experience in orthopaedics and rehabilitation, they assess individual needs to recommend the most appropriate treatments. This collaborative, team-based approach ensures patients receive thorough information, personalised care, and clear guidance.

In summary, ChondroFiller holds great promise for those with certain types of cartilage damage. But selecting the right patients through careful assessment is essential to achieve safe and effective outcomes. Consulting experienced professionals and exploring all treatment options helps patients make informed decisions that best suit their unique circumstances.

References

• Corain, M., Zanotti, F., Giardini, M., Gasperotti, L., Invernizzi, E., Biasi, V., & Lavagnolo, U. (2023). The Use of an Acellular Collagen Matrix ChondroFiller® Liquid for Trapeziometacarpal Osteoarthritis. Cartilage. https://doi.org/10.1177/19476035251354926
• Perez-Carro, L., Rosi Mendoza Alejo, P., Gutierrez Castanedo, G., Menendez Solana, G., Fernandez Divar, J. A., Galindo Rubin, P., & Alfonso Fernandez, A. (2021). Hip Chondral Defects: Arthroscopic Treatment With the Needle and Curette Technique and ChondroFiller. Arthroscopy Techniques, 10(6), e1412–e1416. https://doi.org/10.1016/j.eats.2021.03.011
• De Lucas Villarrubi, J. C., Méndez Alonso, M. Á., Sanz Pérez, M. I., Trell Lesmes, F., & Panadero Tapia, A. (2021). Acellular Matrix-Induced Chondrogenesis Technique Improves the Results of Chondral Lesions Associated With Femoroacetabular Impingement. Arthroscopy: The Journal of Arthroscopic & Related Surgery, 37(12), 3706-3716. https://doi.org/10.1016/j.arthro.2021.08.022